Article
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
EBioMedicine - 1 Aug 2016
Hellner Karin, Miranda Fabrizio, Fotso Chedom Donatien, Herrero-Gonzalez Sandra, Hayden Daniel M, Tearle Rick, Artibani Mara, Carrami Eli M, Williams Ruth, Gaitskell Kezia, Elorbany Samar, Xu Ruoyan, Laios Alex, Buiga Petronela, Ahmed Karim, Dhar Sunanda, Zhang Rebecca Yu, Campo Leticia, Myers Kevin A, Lozano María, Ruiz-Miró María, Gatius Sónia, Mota Alba, Moreno-Bueno Gema, Matias-Guiu Xavier, Benítez Javier, Witty Lorna, McVean Gil, Leedham Simon, Tomlinson Ian, Drmanac Radoje, Cazier Jean-Baptiste, Klein Robert, Dunne Kevin, Bast Robert C, Kennedy Stephen H, Hassan Bassim, Lise Stefano, Garcia María José, Peters Brock A, Yau Christopher, Sauka-Spengler Tatjana, Ahmed Ahmed Ashour
Abstract excerpt
Current screening methods for ovarian cancer can only detect advanced disease. Earlier detection has proved difficult because the molecular precursors involved in the natural history of the disease are unknown. To identify early driver mutations in ovarian cancer cells, we used dense whole genome sequencing of micrometastases and microscopic residual disease collected at three time points over three years from a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
